Hexamethylene bisacetamide (Synonyms: HMBA, NSC 95580) |
| Catalog No.GC49027 |
L'hexaméthylène bisacétamide est un agent de différenciation des cellules tumorales.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3073-59-4
Sample solution is provided at 25 µL, 10mM.
Hexamethylene bisacetamide is a tumor cell-differentiating agent.1 It induces complete differentiation of 754A murine erythroleukemia cells when used at a concentration of 5 mM. Hexamethylene bisacetamide also induces latent HIV-1 viral production in chronically HIV-1-infected U1 cells in a concentration-dependent manner.2 Implantation of HT-29 colon cancer cells cultured with hexamethylene bisacetamide for seven, but not 28, days reduces tumorigenesis of those cells in mice.3
References:
1.Reuben, R.C., Wife, R.L., Breslow, R., et al.A new group of potent inducers of differentiation in murine erythroleukemia cellsProc. Natl. Acad. Sci. USA73(3)862-866(1976)
2.Contreras, X., Barboric, M., Lenasi, T., et al.HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcriptionPLoS Pathog.3(10)1459-1469(2007)
3.Schroy, P., Winawer, S., and Friedman, E.Effect on in vivo tumorigenicity of lengthy exposure of human colon cancer cells to the differentiation agent hexamethylene bisacetamideCancer Lett.48(1)53-58(1989)
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *